NYSE$MTNB
Matinas BioPharma Holdings Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Matinas BioPharma reported results for Q1 2023, with a focus on pipeline development and financial position.
Matinas BioPharma reported a net loss for Q1 2023, with ongoing focus on advancing their pipeline, including MAT2203 and MAT2025. The company highlighted its financial stability with sufficient cash reserves to support operations into the second quarter of 2024.
- Reported a net loss of $7.3 million for the first quarter of 2023.
- Cash and cash equivalents totaled $34.9 million as of March 31, 2023.
- Advanced enrollment in the Phase 2 EnACT trial for MAT2203.
- Continued preclinical development of MAT2025 for mitochondrial dysfunction.
Headline financials
Revenue & EPS history
Matinas BioPharma · Revenue · Quarterly
$1.1M
Forward guidance
Matinas BioPharma anticipates that its existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into the second quarter of 2024.
Tailwinds
- Cash runway extends into the second quarter of 2024.
- Advancing the Phase 2 EnACT trial for MAT2203.
- Progressing preclinical development of MAT2025.
- Exploring potential partnerships to maximize the value of its assets.
- Focusing on efficient use of capital to support key programs.
Headwinds
- Reliance on successful clinical trial outcomes for pipeline advancement.
- Dependence on future financing or partnerships to sustain operations beyond the current cash runway.
- Potential delays or setbacks in clinical development programs.
- Uncertainties related to regulatory approvals for drug candidates.
- Risks associated with competitive landscape and market acceptance of new therapies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-2.1%
Avg return
Earnings day
-2.9%
Avg return
5 days after
-1.9%
Avg return
30 days after
37%
14 / 38 earnings
Positive
+43.0%
Q2 2025
Best reaction
-41.3%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +2.6% | +4.3% | -32.2% | |
| Q2 2025 | +43.0% | +5.5% | +10.9% | |
| Q2 2024 | -1.3% | +9.0% | +17.3% | |
| Q1 2025 | +6.3% | +2.5% | +15.0% | |
| Q4 2025 | -6.0% | -7.5% | +21.2% | |
| Q3 2024 | -15.0% | -18.1% | -23.9% | |
| Q1 2024 | -1.1% | -1.1% | -10.7% | |
| Q4 2023 | -5.2% | +29.4% | -37.4% | |
| Q3 2023 | -24.3% | -31.9% | -21.9% | |
| Q2 2023 | -41.3% | -50.0% | -50.9% | |
| Q1 2023 | -12.5% | -15.5% | -26.0% | |
| Q4 2022 | +2.1% | -11.1% | -2.2% | |
| Q3 2022 | -3.3% | -5.0% | -15.2% | |
| Q2 2022 | -4.7% | -8.4% | -12.9% | |
| Q1 2022 | +6.7% | +6.5% | +32.0% | |
| Q4 2021 | +12.9% | +6.9% | +40.0% | |
| Q3 2021 | -6.8% | -2.8% | +3.7% | |
| Q2 2021 | -2.5% | -5.7% | +2.7% | |
| Q1 2021 | +2.6% | -3.8% | +7.1% | |
| Q4 2020 | -2.7% | -1.8% | -98.3% | |
| Q3 2020 | -2.6% | -3.6% | +29.0% | |
| Q2 2020 | -3.8% | -7.2% | -22.0% | |
| Q1 2020 | +8.9% | +11.7% | +29.7% | |
| Q4 2019 | -14.6% | -34.0% | -49.1% | |
| Q3 2019 | -4.8% | +31.2% | +96.8% | |
| Q2 2019 | +6.2% | +6.7% | +2.1% | |
| Q1 2019 | +1.8% | +10.0% | -7.8% | |
| Q4 2018 | -0.9% | -1.8% | -7.2% | |
| Q3 2018 | -25.2% | -29.8% | -28.8% | |
| Q2 2018 | -1.4% | +5.0% | +26.1% | |
| Q1 2018 | -1.0% | +0.6% | +8.6% | |
| Q4 2017 | -5.5% | -12.8% | -38.8% | |
| Q3 2017 | +2.6% | +4.4% | +24.6% | |
| Q2 2017 | +14.4% | +5.6% | +9.6% | |
| Q1 2017 | +2.9% | +7.6% | -7.3% | |
| Q3 2016 | -6.3% | -4.0% | -20.0% | |
| Q2 2016 | +3.2% | +1.5% | +64.7% | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro